Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$20.49 - $35.63 $5.86 Million - $10.2 Million
-286,195 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$18.99 - $33.2 $5.43 Million - $9.5 Million
286,195 New
286,195 $9.12 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Darwin Global Management, Ltd. Portfolio

Follow Darwin Global Management, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Darwin Global Management, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Darwin Global Management, Ltd. with notifications on news.